{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T06:19:20Z","timestamp":1770358760351,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: The optimal duration of neoadjuvant therapy for high-risk colorectal liver metastases (CRLM) remains debated. While prolonged chemotherapy may enhance response, it also increases toxicity and risks delaying potentially curative resection. These considerations have raised the question whether a short-course neoadjuvant strategy might achieve sufficient oncologic selection and response while minimizing treatment-related morbidity. Methods: Patients with synchronous or metachronous CRLM who received two cycles of neoadjuvant CAPOX plus bevacizumab followed by curative-intent liver resection treated between 2014 and 2024 at Health Network Vienna, Austria, were included. Clinicopathologic characteristics, treatment tolerability, response assessments (biochemical, radiologic, and pathologic), and survival outcomes were collected and analyzed. Results: A total of 57 patients were included (65% synchronous, 35% metachronous), with the rectum being the most frequent primary tumor site (45.6%). Most liver lesions were &lt;5 cm (84.2%), and 47% had bilobar disease. Minor hepatectomy was performed in 65% of cases, predominantly via open surgery (72%). Grade \u22653 treatment-related adverse events occurred in 6 patients (10.6%), mainly neutropenia and diarrhea. Biochemically, 53.7% achieved &gt;50% tumor marker reduction. Radiologic assessment showed partial response in 31.6% and complete response in 1.7%. Pathologic evaluation revealed TRG 3 as the most common finding (57.1%), followed by TRG 2 in 22.5%. Subgroup analyses demonstrated significantly improved OS and RFS in patients receiving adjuvant therapy and in those with tumors &lt; 5 cm. Conclusion: A two-cycle, short-course regimen of CAPOX plus bevacizumab proved both effective and safe in high-risk CRLM, achieving meaningful biochemical, radiologic, and pathologic responses with acceptable toxicity. This abbreviated approach allowed delivery of neoadjuvant therapy while limiting cumulative treatment-related toxicity, supporting its feasibility as a neoadjuvant strategy in selected high-risk CRLM patients.<\/jats:p>","DOI":"10.3390\/cancers18030521","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:24:19Z","timestamp":1770305059000},"page":"521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncologic and Surgical Outcomes After Short-Course Neoadjuvant CAPOX Plus Bevacizumab in High-Risk Colorectal Liver Metastases"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-1228","authenticated-orcid":false,"given":"Yawen","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madita","family":"Tschoegl","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0956-1979","authenticated-orcid":false,"given":"Florian","family":"Lehner","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-1782","authenticated-orcid":false,"given":"Francesca","family":"Notte","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariel","family":"Gramberger","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Salem","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edanur","family":"Cenan","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Thonhauser","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hoblaj","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemarie","family":"Valenta","sequence":"additional","affiliation":[{"name":"Department of Radiology, Clinic Favoriten, Health Network Vienna, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Gruenberger","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital Wiener Neustadt, 2700 Wiener Neustadt, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2671-0540","authenticated-orcid":false,"given":"Thomas","family":"Gruenberger","sequence":"additional","affiliation":[{"name":"Department of Surgery, HPB Center, Clinic Favoriten, Health Network Vienna and Sigmund Freud Private University, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","first-page":"e000813","article-title":"How We Treat Metastatic Colorectal Cancer","volume":"4","author":"Napolitano","year":"2020","journal-title":"ESMO Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of Metastatic Colorectal Cancer: ASCO Guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/SLA.0000000000006884","article-title":"Benchmarking Oncologic Outcomes of Liver Resection for Colorectal Metastases: LiverMetSurvey-Based Reference Values for Evaluating Alternative Treatments","volume":"282","author":"Risi","year":"2025","journal-title":"Ann. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102382","DOI":"10.1016\/j.ctrv.2022.102382","article-title":"The Management of Colorectal Liver Metastases Amenable of Surgical Resection: How to Shape Treatment Strategies According to Clinical, Radiological, Pathological and Molecular Features","volume":"106","author":"Germani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12957-019-1641-5","article-title":"Optimal Indication Criteria for Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases","volume":"17","author":"Ichida","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3748\/wjg.v30.i7.663","article-title":"Current Landscape of Preoperative Neoadjuvant Therapies for Initial Resectable Colorectal Cancer Liver Metastasis","volume":"30","author":"Cheng","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_7","first-page":"255","article-title":"A Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal Cancer","volume":"31","author":"Wong","year":"2011","journal-title":"Anticancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2007.13.7679","article-title":"Bevacizumab, Capecitabine, and Oxaliplatin as Neoadjuvant Therapy for Patients with Potentially Curable Metastatic Colorectal Cancer","volume":"26","author":"Gruenberger","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab Plus MFOLFOX6 Versus MFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial","volume":"38","author":"Tang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance Treatment with Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (CAIRO3): A Phase 3 Randomised Controlled Trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452551","article-title":"Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis","volume":"40","author":"Zhou","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Volk, A.M., Fritzmann, J., Reissfelder, C., Weber, G.F., Weitz, J., and Rahbari, N.N. (2016). Impact of Bevacizumab on Parenchymal Damage and Functional Recovery of the Liver in Patients with Colorectal Liver Metastases. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2095-6"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2559.2010.03511.x","article-title":"Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia Are Frequent Oxaliplatin-Associated Liver Lesions and Partially Prevented by Bevacizumab in Patients with Hepatic Colorectal Metastasis","volume":"56","author":"Lauwers","year":"2010","journal-title":"Histopathology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.ejso.2018.07.050","article-title":"Impact of Biological Agents on the Prevalence of Chemotherapy Associated Liver Injury (CALI): Multicentric Study of Patients Operated for Colorectal Liver Metastases","volume":"44","author":"Hubert","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1245\/s10434-006-9074-0","article-title":"Lack of Evidence for Increased Operative Morbidity after Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study","volume":"14","author":"Kornprat","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dong, Y., Santol, J., Gruenberger, B., Lenauer, A., Laengle, F., Thaler, J., Piringer, G., Eisterer, W., Djanani, A., and Stift, J. (2024). Perioperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer: Long-Term Follow-Up of the ASSO-LM1 Trial. Cancers, 16.","DOI":"10.3390\/cancers16050857"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1008378412533","article-title":"CEA and CA 19-9 Measurement as a Monitoring Parameter in Metastatic Colorectal Cancer (CRC) under Palliative First-Line Chemotherapy with Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil (5-FU) and Folinic Acid (FA)","volume":"12","author":"Hanke","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.clon.2003.11.005","article-title":"Any Clinical Benefit from the Use of Oncofoetal Markers in the Management of Chemotherapy for Patients with Metastatic Colorectal Carcinomas?","volume":"16","author":"Chapuis","year":"2004","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1001\/jama.2009.1755","article-title":"Association of Computed Tomography Morphologic Criteria with Pathologic Response and Survival in Patients Treated with Bevacizumab for Colorectal Liver Metastases","volume":"302","author":"Chun","year":"2009","journal-title":"JAMA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1200\/JCO.2012.45.2854","article-title":"Optimal Morphologic Response to Preoperative Chemotherapy: An Alternate Outcome End Point before Resection of Hepatic Colorectal Metastases","volume":"30","author":"Shindoh","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdl386","article-title":"Importance of Histological Tumor Response Assessment in Predicting the Outcome in Patients with Colorectal Liver Metastases Treated with Neo-Adjuvant Chemotherapy Followed by Liver Surgery","volume":"18","author":"Giostra","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1245\/s10434-010-0972-9","article-title":"Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX\/FOLFOX","volume":"17","author":"Klinger","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Thonhauser, R., Poglitsch, M., Jonas, J.P., Dong, Y., Tsch\u00f6gl, M., Gramberger, M., Salem, M., Santol, J., Brandl, I., and Klimpfinger, M. (2023). The Effect of Induction Chemotherapy with VEGF Inhibition on Tumor Response in Synchronously Metastasized Potentially Resectable Colorectal Cancer. Cancers, 15.","DOI":"10.3390\/cancers15112900"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.suronc.2012.07.003","article-title":"Pathologic Response to Bevacizumab-Containing Chemotherapy in Patients with Colorectal Liver Metastases and Its Correlation with Survival","volume":"21","author":"Gruenberger","year":"2012","journal-title":"Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1365-182X(17)30755-4","article-title":"The Brisbane 2000 Terminology of Liver Anatomy and Resections","volume":"2","author":"Strasberg","year":"2000","journal-title":"HPB"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of Surgical Complications: A New Proposal with Evaluation in a Cohort of 6336 Patients and Results of a Survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_28","unstructured":"National Cancer Institute (2025, December 01). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/SLA.0b013e3181deb67f","article-title":"Liver Resection Remains a Safe Procedure after Neoadjuvant Chemotherapy Including Bevacizumab: A Case-Controlled Study","volume":"252","author":"Tamandl","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1470-2045(13)70447-9","article-title":"Perioperative FOLFOX4 Chemotherapy and Surgery versus Surgery Alone for Resectable Liver Metastases from Colorectal Cancer (EORTC 40983): Long-Term Results of a Randomised, Controlled, Phase 3 Trial","volume":"14","author":"Nordlinger","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Papakonstantinou, M., Fantakis, A., Torzilli, G., Donadon, M., Chatzikomnitsa, P., Giakoustidis, D., Papadopoulos, V.N., and Giakoustidis, A. (2025). A Systematic Review of Disappearing Colorectal Liver Metastases: Resection or No Resection?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041147"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.suronc.2019.02.005","article-title":"Disappearing Liver Metastases: A Systematic Review of the Current Evidence","volume":"29","author":"Tsilimigras","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bjc.2011.201","article-title":"XELOX vs FOLFOX-4 as First-Line Therapy for Metastatic Colorectal Cancer: NO16966 Updated Results","volume":"105","author":"Cassidy","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lee, H.Y., and Woo, I.S. (2021). Perioperative Systemic Chemotherapy for Colorectal Liver Metastasis: Recent Updates. Cancers, 13.","DOI":"10.3390\/cancers13184590"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.semcancer.2020.09.008","article-title":"Limitations in Resectability of Colorectal Liver Metastases 2020\u2014A Systematic Approach for Clinicians and Patients","volume":"71","author":"Schadde","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Nieuwenhuizen, S., Puijk, R.S., van den Bemd, B., Aldrighetti, L., Arntz, M., van den Boezem, P.B., Bruynzeel, A.M.E., Burgmans, M.C., de Cobelli, F., and Coolsen, M.M.E. (2020). Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases: Multidisciplinary Consensus Document from the COLLISION Trial Group. Cancers, 12.","DOI":"10.3390\/cancers12071779"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:33:52Z","timestamp":1770305632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/3\/521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18030521"],"URL":"https:\/\/doi.org\/10.3390\/cancers18030521","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}